title: Model-based assessment of erlotinib effect in vitro measured by real-time cell analysis.
abstract: Real time cell analysis (RTCA) is an impedance-based technology which tracks various living cell characteristics over time, such as their number, morphology or adhesion to the extra cellular matrix. However, there is no consensus about how RTCA data should be used to quantitatively evaluate pharmacodynamic parameters which describe drug efficacy or toxicity. The purpose of this work was to determine how RTCA data can be analyzed with mathematical modeling to explore and quantify drug effect in vitro. The pharmacokinetic-pharmacodynamic erlotinib concentration profile predicted by the model and its effect on the human epidermoïd carcinoma cell line A431 in vitro was measured through RTCA output, designated as cell index. A population approach was used to estimate model parameter values, considering a plate well as the statistical unit. The model related the cell index to the number of cells by means of a proportionality factor. Cell growth was described by an exponential model. A delay between erlotinib pharmacokinetics and cell killing was described by a transit compartment model, and the effect potency, by an E max function of erlotinib concentration. The modeling analysis performed on RTCA data distinguished drug effects in vitro on cell number from other effects likely to modify the relationship between cell index and cell number. It also revealed a time-dependent decrease of erlotinib concentration over time, described by a mono-exponential pharmacokinetic model with nonspecific binding.
authors.affiliation: Pharmacokinetics Unit, SMARTc, Inserm CRO2 UMR S 911, Aix-Marseille University, 13385, Marseille, France.
authors.forename: Stephan
authors.initials: S
authors.lastname: Benay
authors.forename: Christophe
authors.initials: C
authors.lastname: Meille
authors.forename: Stefan
authors.initials: S
authors.lastname: Kustermann
authors.forename: Isabelle
authors.initials: I
authors.lastname: Walter
authors.forename: Antje
authors.initials: A
authors.lastname: Walz
authors.forename: P Alexis
authors.initials: PA
authors.lastname: Gonsard
authors.forename: Elina
authors.initials: E
authors.lastname: Pietilae
authors.forename: Nicole
authors.initials: N
authors.lastname: Kratochwil
authors.forename: Athanassios
authors.initials: A
authors.lastname: Iliadis
authors.forename: Adrian
authors.initials: A
authors.lastname: Roth
authors.forename: Thierry
authors.initials: T
authors.lastname: Lave
mesh_terms: D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D003199:Computer Systems; D000069347:Erlotinib Hydrochloride / Q000493:pharmacokinetics*; D006801:Humans; D008954:Models, Biological; D047428:Protein Kinase Inhibitors / Q000493:pharmacokinetics*
chemical_list: D047428:Protein Kinase Inhibitors; D000069347:Erlotinib Hydrochloride
references.citation: Cell Cycle. 2009 Jan 1;8(1):18-22
references.pmid: 19106609
references.citation: Methods Mol Biol. 2007;356:415-25
references.pmid: 16988420
references.citation: Clin Cancer Res. 2014 Jul 15;20(14 ):3742-52
references.pmid: 24812409
references.citation: ILAR J. 2010;51(3):214-20
references.pmid: 21131722
references.citation: Methods Mol Biol. 2011;740:33-43
references.pmid: 21468966
references.citation: Clin Pharmacol Ther. 2006 Aug;80(2):136-45
references.pmid: 16890575
references.citation: J Mol Med (Berl). 2014 Nov;92 (11):1209-23
references.pmid: 25091467
references.citation: PLoS One. 2012;7(6):e38770
references.pmid: 22701710
references.citation: Biochim Biophys Acta. 2011 May;1813(5):754-62
references.pmid: 21262275
references.citation: Mol Cancer Ther. 2007 Aug;6(8):2168-77
references.pmid: 17671085
references.citation: Anal Chim Acta. 2013 Feb 18;764:44-52
references.pmid: 23374213
references.citation: Lung Cancer. 2013 Sep;81(3):328-36
references.pmid: 23809060
references.citation: Int J Cancer. 1998 Jan 19;75(2):205-9
references.pmid: 9462709
references.citation: Neoplasia. 2011 Nov;13(11):1026-34
references.pmid: 22131878
references.citation: Toxicol In Vitro. 2013 Aug;27(5):1589-95
references.pmid: 22954529
references.citation: Cancer Res. 2004 Feb 1;64(3):1094-101
references.pmid: 14871843
references.citation: Int J Oncol. 1992 Aug;1(3):293-8
references.pmid: 21584545
references.citation: J Clin Oncol. 2001 Jul 1;19(13):3267-79
references.pmid: 11432895
references.citation: J Biomol Screen. 2011 Jul;16(6):565-74
references.pmid: 21493966
references.citation: AAPS J. 2010 Mar;12(1):1-10
references.pmid: 19902363
references.citation: AAPS PharmSci. 2002;4(4):E42
references.pmid: 12646013
references.citation: Science. 1984 May 25;224(4651):843-8
references.pmid: 6326261
references.citation: IEEE Trans Biomed Eng. 1986 Feb;33(2):242-7
references.pmid: 3957373
references.citation: Toxicol Sci. 2011 Sep;123(1):281-9
references.pmid: 21693436
references.citation: J Cell Sci. 1991 Nov;100 ( Pt 3):491-9
references.pmid: 1808202
references.citation: J Pharm Sci. 2003 May;92(5):967-74
references.pmid: 12712416
references.citation: Math Biosci. 2000 Mar;164(1):17-38
references.pmid: 10704636
references.citation: Nat Rev Drug Discov. 2011 Mar;10(3):221-37
references.pmid: 21358741
references.citation: Cancer Res. 2007 Jun 15;67(12 ):5779-88
references.pmid: 17575145
references.citation: Science. 1994 Aug 19;265(5175):1093-5
references.pmid: 8066447
references.citation: PLoS One. 2014 Feb 05;9(2):e87626
references.pmid: 24505297
references.citation: Biotechnol J. 2008 Apr;3(4):484-95
references.pmid: 18412175
references.citation: Exp Cell Res. 1997 Jun 15;233(2):383-90
references.pmid: 9194500
references.citation: Math Biosci. 1998 Jan 1;147(1):41-61
references.pmid: 9401351
references.citation: J Biomol Screen. 2011 Mar;16(3):313-22
references.pmid: 21310850
references.citation: Anal Chim Acta. 2008 May 12;615(1):80-7
references.pmid: 18440366
references.citation: Assay Drug Dev Technol. 2006 Oct;4(5):597-607
references.pmid: 17115930
references.citation: Clin Pharmacol Ther. 2008 Jun;83(6):909-12
references.pmid: 18388873
references.citation: J Clin Invest. 2008 Jul;118(7):2609-19
references.pmid: 18568074
references.citation: Am J Cancer Res. 2014 Sep 06;4(5):411-35
references.pmid: 25232485
references.citation: J Pharm Sci. 2011 Jun;100(6):2498-507
references.pmid: 21213309